Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Guided Therapeutics Inc

Company price
0.11 USD -0.01 ( 8.33%)
Last update at 2026-11-13T18:17:00Z
VOLUME
11625
Market Cap
24.13M

Momentum Score

…

Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.10
Low
0.11
High
52 Week Price Range
0.15
Low
0.54
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Guided Therapeutics Inc is a small medical-device company that develops non-invasive optical diagnostic technology aimed at detecting cervical disease and improving screening workflows. Long-term growth drivers may include wider adoption of point-of-care screening, potential regulatory clearances or reimbursement, and partnerships to scale commercialization, which could make the company attractive to investors seeking exposure to niche diagnostic technologies.

Material risks include limited public information and liquidity, dependence on regulatory approvals and successful commercialization, and the need for additional financing to sustain operations.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.12
Dividend Yield
-
Revenue TTM
0.65M
Revenue Per Share
0.01
Gross Profit TTM
0.49M
Debt / Equity
-
ROE
-
Net Debt
2.18M
ROCE
44.65%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -3.20M -2.42M -3.49M -4.34M -2.07M
Net income -3.20M -2.42M -3.49M -4.34M -2.07M
Selling general administrative 2.47M 1.58M 3.27M 3.19M 2.31M
Gross profit 0.57M 0.00M 0.04M -0.07M 0.02M
Reconciled depreciation 0.11M 0.10M 0.09M 0.07M 0.08M
Ebit - - - - -2.36M
Ebitda - - - -3.69M -0.84M
Operating income -2.37M -2.11M -3.46M -3.33M -2.36M
Interest expense 0.62M 0.38M 0.28M 0.58M 1.15M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.00M 0.00M 0.01M 0.00M -
Net interest income -0.62M -0.38M -0.27M -0.58M -1.15M
Total revenue 0.77M 0.01M 0.10M 0.01M 0.08M
Total operating expenses 3.14M 2.12M 3.56M 3.35M 2.44M
Cost of revenue 0.20M 0.01M 0.06M 0.08M 0.06M
Total other income expense net -0.21M 0.07M 0.24M -0.43M 1.44M
Net income from continuing ops -3.20M -2.42M -3.49M -4.34M -2.07M
Net income applicable to common shares - - - - -2.43M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1.32M 1.38M 1.67M 3.37M 2.04M
Other current assets 0.09M 0.17M 0.16M 0.14M 0.38M
Total liab 7.33M 6.27M 5.47M 6.25M 7.49M
Total stockholder equity -6.01M -4.89M -3.81M -2.88M -5.45M
Other current liab 0.04M 0.12M - - 1.04M
Common stock - - - - 3.40M
Capital stock 5.09M 6.45M 6.46M 6.52M 10.27M
Retained earnings -157.06M -153.71M -151.12M -147.36M -142.39M
Other liab - - - - 0.03M
Other assets - - - - 0.02M
Cash 0.06M 0.39M 0.59M 2.31M 0.64M
Total current liabilities 6.64M 6.16M 4.81M 4.87M 5.69M
Net debt 2.18M 1.62M 1.12M - 1.86M
Short long term debt 2.20M 1.94M 1.20M 0.81M 1.07M
Property plant equipment - - - - 0.39M
Total current assets 0.60M 1.20M 1.39M 3.00M 1.64M
Net tangible assets - - - - -12.32M
Net receivables 0.00M 0.00M 0.01M 0.01M 0.05M
Long term debt 0.04M 0.06M 0.51M 1.13M 1.43M
Inventory 0.45M 0.63M 0.63M 0.55M 0.57M
Accounts payable 2.45M 2.13M 2.02M 2.23M 2.45M
Non currrent assets other 0.02M 0.02M 0.02M 0.02M 0.02M
Non current assets total 0.72M 0.18M 0.28M 0.36M 0.40M
Capital lease obligations 0.70M 0.15M 0.25M 0.33M 0.39M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - 0.00M -0.03M -0.01M
Change to liabilities - - - - 0.43M
Total cashflows from investing activities - - - - -0.01M
Net borrowings 0.21M 0.11M -0.41M -0.54M -0.22M
Total cash from financing activities 0.74M 0.92M 0.02M 3.18M 2.07M
Change to operating activities - - - - -0.36M
Net income -3.20M -2.42M -3.49M -4.34M -2.07M
Change in cash -0.33M -0.20M -1.72M 1.67M 0.46M
Begin period cash flow 0.39M 0.59M 2.31M 0.64M 0.18M
End period cash flow 0.06M 0.39M 0.59M 2.31M 0.64M
Total cash from operating activities -1.07M -1.12M -1.75M -1.48M -1.59M
Issuance of capital stock - - 0.00M 1.39M 2.10M
Depreciation 0.11M 0.10M 0.09M 0.07M 0.08M
Change to inventory 0.18M -0.00M -0.08M -0.06M 0.03M
Change to account receivables -0.01M 0.01M -0.00M 0.02M -0.02M
Sale purchase of stock - - - 0.00M -0.12M
Other cashflows from financing activities - - - - 0.31M
Change to netincome - - - - -0.01M
Capital expenditures 0.00M 0.00M 0.00M 0.03M 0.01M
Change in working capital 0.99M 1.00M -0.10M 0.55M 0.08M
Stock based compensation 0.38M 0.12M 1.81M 1.38M 0.23M
Other non cash items 0.28M 0.13M 0.16M 0.32M -0.13M
Free cash flow -1.07M -1.12M -1.75M -1.51M -1.61M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GTHP
Guided Therapeutics Inc
-0.01
8.33%
0.11 - - 37.13 106.31 42.50 -5.60
ABT
Abbott Laboratories
1.27
1.18%
108.52 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
1.87
1.85%
102.86 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-2.75
0.88%
309.64 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-0.27
0.55%
48.51 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Guided Therapeutics Inc

Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.

5835 Peachtree Corners East, Peachtree Corners, GA, United States, 30092

770 242 8723

3

Name Title Year Born
Dr. Mark L. Faupel Ph.D. CEO, President, COO, Acting CFO, Secretary & Director 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…